About one-third of U.S. adults take a daily multivitamin, often to fill nutritional gaps or as a form of “insurance.” While ...

Despite substantial advances in guideline-directed medical therapy, recurrent hospitalization remains a persistent challenge in the management of congestive heart failure (CHF). Fluid overload is ...

Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

Little is known about the initial dosing of loop diuretics among patients hospitalized for heart failure and its association with outcomes. Despite decades of experience with intravenous loop ...

The analysis included 120 veterans (66 years and older) who potentially experienced the gabapentinoid-LD prescribing cascade. HealthDay News — The potential downstream harms in the gabapentinoid ...

Clinicians may fail to recognize common side effects of drugs like gabapentin — which are frequently prescribed for nerve pain — leading them to prescribe unnecessary medications that cause yet more ...

Furosemide, a highly protein-bound organic acid, promotes free water clearance and natriuresis by entering the proximal tubules of the kidneys and blocking the sodium-potassium-chloride ...

Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with ...

Enbumyst is not intended for chronic use and should be replaced with oral diuretics as soon as practical. The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of ...